Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $140.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective lifted by Piper Sandler from $125.00 to $140.00 in a report published on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other equities analysts have also weighed in on KYMR. Truist Financial raised their price objective on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. B. Riley Financial lifted their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. UBS Group raised shares of Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. Mizuho raised their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Finally, JPMorgan Chase & Co. boosted their price objective on Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $117.60.

Kymera Therapeutics Trading Down 3.9%

NASDAQ KYMR opened at $91.35 on Thursday. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $103.00. The firm has a market capitalization of $6.57 billion, a P/E ratio of -24.82 and a beta of 2.21. The business has a fifty day simple moving average of $78.52 and a 200 day simple moving average of $65.44.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 34.12%. The firm’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.88) earnings per share. As a group, sell-side analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 229,809 shares of the stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total transaction of $21,080,379.57. Following the transaction, the director owned 686,477 shares of the company’s stock, valued at approximately $62,970,535.21. This trade represents a 25.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $86.00 per share, for a total transaction of $172,499,918.00. Following the transaction, the director owned 7,955,916 shares in the company, valued at $684,208,776. This trade represents a 33.71% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders sold 450,895 shares of company stock valued at $40,486,151. 16.01% of the stock is currently owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its stake in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC grew its position in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. grew its position in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. increased its stake in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares during the period.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced its degrader candidate KT‑579 has entered first‑in‑human (Phase 1) testing — an important de‑risking milestone that validates the Pegasus platform and expands the company’s clinical-stage pipeline. Article Title
• Positive Sentiment: Management reported a large cash infusion (~$1.6B) that materially extends the company’s cash runway into 2029 and supports planned development (including KT‑621), reducing near‑term dilution risk. This funding, combined with ongoing program progress, is a key positive for valuation and execution. Article Title
• Positive Sentiment: Analyst sentiment remains constructive: Piper Sandler raised its price target to $140 and the consensus analyst posture is still broadly a “Buy,” supporting potential upside from upgrades and model revisions. Article Title
• Neutral Sentiment: Kymera reiterated plans to read out KT‑621 Phase IIb data in 2027 — a clear catalyst for 2027 but distant; this keeps the company in a development‑stage timeline where interim updates will matter to sentiment. Article Title
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.97) vs. consensus ($0.77) and revenue of $2.87M vs. $14.8M (down ~60% y/y). The larger loss and revenue shortfall triggered near‑term selling and raises questions on near‑term commercial/collaboration cadence. Article Title
• Negative Sentiment: Insider selling: CEO Nello Mainolfi sold 30,000 shares (~$2.7M). While not uncommon for executives to monetize, multiple recent sales may weigh on investor sentiment in the short term. Article Title

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.